According to recent research, investigators have observed that a relatively high proportion of patients were observed with disease progression over a short period of time, highlighting the need for better identification of patients at risk of rapidly progressive CKD, as published in the Clinical Kidney Journal.
Hence, Csaba P Kovesdy and colleagues from the Department of Medicine, Division of Nephrology, University of Tennessee Health Science Center, Memphis, TN, USA conducted this population cohort study to assess the Chronic kidney disease progression among patients with type 2 diabetes identified in US administrative claims. A total of 65 731 and 23 035 patients with T2D contributed to the analysis of eGFR- and UACR-based CKD stage progression, respectively.
The authors included patients with T2D and laboratory evidence of CKD as indicated by the established estimated glomerular filtration rate (eGFR) and urine albumin: creatinine ratio (UACR) criteria. Disease progression was described as transitions across the eGFR- and UACR-based stages.
The observations were-
a. CKD worsening was observed in approximately 10–17% of patients over a median follow-up of 2 years.
b. Approximately one-third of patients experienced an increase in eGFR values or a decrease in UACR values during follow-up.
Therefore, the authors concluded that "A relatively high proportion of patients were observed with disease progression over a short period of time, highlighting the need for better identification of patients at risk of rapidly progressive CKD. Future studies are needed to determine the clinical characteristics of these patients to inform earlier diagnostic and therapeutic interventions aimed at slowing disease progression."
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.